Longevity Pulse
Academic PapersReviewsVideosPodcastsPress ReleasesClinical TrialsDrug ApprovalsTutorialsAnimations
All Articles
TutorialsClinical TutorialsVideosContinuous Listen
Free Subscription
Sign In
Deep Dive Audio
FDA adds NAION eye warning to GLP-1 drugs, leaving patients and doctors in a bindLongevity & Aging

FDA adds NAION eye warning to GLP-1 drugs, leaving patients and doctors in a bind

The FDA announced on November 9 that all GLP-1 drugs, including semaglutide and tirzepatide, must carry new warnings about a possible increased risk of NAION, a rare form of sudden, painless vision loss caused by reduced blood flow to the optic nerve. This opinion piece, by ophthalmologist Henry Bair, argues the warning is welcome but incomplete. Across 126 clinical trials, the FDA found 15 probable cases: about six per 100,000 patient-years on GLP-1 drugs versus four on placebo or other diabetes drugs. Observational studies also raise concern, but they cannot fully separate drug effects from the underlying conditions. No one knows whether continuing a GLP-1 after NAION raises risk in the other eye, or whether stopping lowers it. Bair urges the FDA to study outcomes after stopping, continuing or switching. Until then, he recommends that patient, eye doctor and prescriber weigh the decision together.

0:00--:--
Read Full Article
Longevity Pulse

Developed by the Clinical and Foundational Medicine Institute

AI-powered summaries of the world's best longevity research — from peer-reviewed journals to expert podcasts and YouTube deep-dives. Built for those who take their healthspan seriously.

info@LongevityToday.com

Categories

CancerHeart DiseaseAlzheimer'sParkinson'sDiabetesGut HealthNutritionStrength & FitnessSupplements & PeptidesStem CellsReversing AgingAuto-ImmunityAdvanced Therapies

Platform

  • All Articles
  • Membership Plans
  • Search
  • Newsletter

Newsletter

Weekly longevity research, summarized.

Enter your email to subscribe:

© 2026 Longevity Pulse. All rights reserved.

About UsPrivacy PolicyTerms of UseMedical Disclaimer

Content on Longevity Pulse is for informational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before making health decisions.